Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Investigation of Chimeric CD(Cluster of Differentiation)33 Antigen Receptor-modified NK92 Cells in Relapsed and/or Refractory Acute Myeloid Leukemias

NCT02944162 is registered in ClinicalTrials.gov with PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT02944162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02944162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Investigation of Chimeric CD(Cluster of Differentiation)33 Antigen Receptor-modified NK92 Cells in Relapsed and/or Refractory Acute Myeloid Leukemias
Lead sponsor
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 31, 2016
Completion date
September 30, 2018
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, acute myeloid leukemia, acute myeloid leukemia with maturation, acute myeloid leukemia without maturation, anll